Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
SABCS Highlights
Ribociclib plus Endocrine Regimen Outperforms Combination Chemotherapy in Advanced Breast Cancer
By
Phoebe Starr
SABCS Highlights
,
Breast Cancer
February 2023, Vol 14, No 1
Patients with hormone receptor (HR)-positive,
HER2
-negative advanced breast cancer, including those with visceral crises, treated with the CDK4/6 inhibitor ribociclib (Kisqali) plus endocrine therapy had a significantly longer progression-free survival (PFS) and fewer adverse events (AEs) compared with those treated with combination chemotherapy, according to results from the phase 2 RIGHT Choice trial.
Read Article
CTC Count May Help Physicians Choose Treatment for Patients with Metastatic Breast Cancer
By
Wayne Kuznar
SABCS Highlights
,
Breast Cancer
February 2023, Vol 14, No 1
Using circulating tumor cell (CTC) count to guide the choice of first-line treatment—chemotherapy or endocrine therapy—improved overall survival (OS) compared with investigator’s choice of treatment for patients with metastatic, estrogen receptor (ER)-positive,
HER2
-negative breast cancer, according to results from the STIC CTC trial, which were discussed at the 2022 San Antonio Breast Cancer Symposium (SABCS) by François-Clément Bidard, MD, PhD, Co-Coordinator, Breast Cancer Research, Institut Curie, Paris, France, and Professor, Medicine, Department of Medical Oncology, Institut Curie and Université de Versailles Saint-Quentin-en-Yvelines, France.
Read Article
Trastuzumab Deruxtecan Promising in Patients with HER2-Positive Breast Cancer and Brain Metastases
By
Phoebe Starr
SABCS Highlights
February 2022, Vol 13, No 1 Online Only
Second-line therapy with trastuzumab deruxtecan (Enhertu; T-DXd) extended progression-free survival (PFS) and improved objective response rate (ORR) versus trastuzumab emtansine (Kadcyla; T-DM1) in women with
HER2
-positive metastatic breast cancer, including those with stable brain metastasis at baseline, according to a subgroup analysis of a phase 3 clinical trial.
Read Article
KEYNOTE-355: Pembrolizumab plus Chemotherapy Extends Survival in Patients with Triple-Negative Breast Cancer and PD-L1 Combined Positive Score ≥10
By
Phoebe Starr
SABCS Highlights
February 2022, Vol 13, No 1 Online Only
Final results from the pivotal phase 3 KEYNOTE-355 trial showed that the addition of pembrolizumab (Keytruda) to chemotherapy resulted in a statistically significant and clinically meaningful improvement in overall survival (OS) compared with chemotherapy alone in patients with metastatic triple-negative breast cancer (TNBC) whose tumors expressed PD-L1 with a combined positive score (CPS) ≥10.
Read Article
CDK4/6 Inhibitors in HER2+ Metastatic Breast Cancer
By
Dr Matthew Goetz
Breast Cancer
,
SABCS Highlights
Videos
Dr Matthew Goetz addresses the prospect of utilizing CDK4/6 inhibitors to treat patients with HER2+ metastatic breast cancer, stating early data indicate that CDK4/6 inhibitors may have some antitumor activity in HER2+ breast cancer.
Read Article
Questions About Treating Patients Using a CDK4/6 Inhibitor
By
Dr Matthew Goetz
Breast Cancer
,
SABCS Highlights
Videos
Dr Matthew Goetz addresses common questions that arise when patients with HER-positive metastatic breast cancer have progressed on a CDK4/6 inhibitor plus an aromatase inhibitor.
Read Article
Abemaciclib, Ribociclib, or Palbociclib for HR+ Metastatic Breast Cancer?
By
Dr Matthew Goetz
Breast Cancer
,
SABCS Highlights
Videos
Dr Matthew Goetz reviews what differentiates abemaciclib, the latest CDK4/6 inhibitor FDA approved for HR+ metastatic breast cancer, from ribociclib and palbociclib.
Read Article
The Use of Chemotherapy in the Metastatic Setting
By
Dr Matthew Goetz
Breast Cancer
,
SABCS Highlights
Videos
Dr Matthew Goetz believes that, as more mature data come into existence, the demonstration of a survival advantage will guide more patients with metastatic breast cancer to try CDK4/6 inhibitors plus aromatase inhibitors instead of chemotherapy.
Read Article
The Mechanism of Action of CDK4/6 Inhibitors
By
Dr Matthew Goetz
Breast Cancer
,
SABCS Highlights
Videos
Dr Matthew Goetz explains the rationale for using CDK4/6 inhibitors in patients with HR-positive metastatic breast cancer.
Read Article
HER2-Positive Breast Cancer and CDK4/6 Inhibitors
By
Dr Hope Rugo
Breast Cancer
,
SABCS Highlights
Videos
Dr Hope Rugo discusses studies that are aiming to evaluate the effect that CDK4/6 inhibitors have on patients with HER2-positive breast cancer.
Read Article
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma